Finance

Lists
QNRX:NASDAQ
Quoin Pharmaceuticals Ltd - ADR
USD 4,50
-1,10%
(-0,050) 1D
USD 4,31
-4,16% (-0,19)
After hours
Closed: 9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QNRX...
Open
USD 4,32
High
USD 4,68
Low
USD 4,25
Mkt. cap
21,62 m
Avg. vol.
1,13 m
Volume
42,58 k
52-wk high
USD 41,80
52-wk low
USD 3,25
EPS
-USD 423,73
Beta
1,56
Shares outstanding
4,80 m
No. of employees
5
Open
USD 4,32
High
USD 4,68
Low
USD 4,25
Mkt. cap
21,62 m
Avg. vol.
1,13 m
Volume
42,58 k
52-wk high
USD 41,80
52-wk low
USD 3,25
EPS
-USD 423,73
Beta
1,56
Shares outstanding
4,80 m
No. of employees
5
News stories
From web sources and news partners
About Quoin Pharmaceuticals Ltd - ADR
CEO-
Employees5
Founded1986
Headquarters-
Sector-
Websitequoinpharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to QNRX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for QNRX in the last 3 months.
Highest
Current USD 4,50
USD 35,00 (+677,78%)
Average
USD 25,00 (+455,56%)
Lowest
USD 20,00 (+344,44%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Flaten
Lake Street
Buy
Initiated
USD 20,00
+344,4%
09/23/2026
Naz Rahman
Maxim Group
Buy
Reiterated
USD 20,00
+344,4%
09/03/2026
James Molloy
Alliance Global Partners
Buy
Reiterated
USD 35,00
+677,8%
08/17/2026
Ashok Kumar
ThinkEquity
Buy
Initiated
USD 12,00
+166,7%
06/15/2026
Dev Prasad
Lucid Capital
Buy
Initiated
USD 30,00
+566,7%
05/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2,28 m
3,10 m
3,43 m
3,63 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 m
1,42 m
1,70 m
1,85 m
Operating expense
4,02 m
4,52 m
5,13 m
5,47 m
Total operating expenses
4,02 m
4,52 m
5,13 m
5,47 m
Operating income
-4,02 m
-4,52 m
-5,13 m
-5,47 m
Other non operating income
9,49 k
364,00
-13,30 k
1,58 k
EBT including unusual items
-3,95 m
-4,35 m
-5,00 m
-5,37 m
EBT excluding unusual items
-3,95 m
-4,35 m
-5,00 m
-5,37 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-3,95 m
-4,35 m
-5,00 m
-5,37 m
Net profit margin
-
-
-
-
Earnings per share
-6,70
-
-1,77
-1,90
Interest and investment income
62,27 k
171,70 k
146,78 k
100,95 k
Interest expense
-
-
-
-
Net interest expenses
62,27 k
171,70 k
146,78 k
100,95 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-3,99 m
-4,50 m
-5,11 m
-5,45 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme